He migrated to Harar first, then settled in the southern part of Omnan which is now a part of Silte. Middle East
Men belonging to the Sayyid families or tribes in the Arab world used to wear white or ivory coloured daggers like jambiyas, khanjars or shibriyas to demarcate their nobility amongst other Arab men, although this custom has been restricted due to the local laws of the variously divided Arab countries. Iraq
The Sayyid families in Iraq are so numerous that there are books written especially to list the families and connect their trees. Some of these families are: the Alyassiri, Al Aqeeqi, Al-Nasrullah, Al-Wahab, Al-Hashimi,Al-Barznji, Al-Quraishi, Al-Marashi, Al-Witry, Al-Obaidi, Al-Samarai, Al-Zaidi, Al-Aaraji, Al-Baka, Al-Hasani, Al-Hussaini, Al-Shahristani, Al-Qazwini Al-Qadri, Tabatabaei, Al- Alawi, Al-Ghawalib (Al-Ghalibi), Al-Musawi, Al-Awadi (not to be confused with the Al-Awadhi Huwala family), Al-Gharawi, Al-Sabzewari, Al-Shubber, Al-Hayali, Al-Kamaludeen and many others. Iran
Sayyids (in Persian: سید Seyyed) are found in vast numbers in Iran. The Chief of "National Organization for Civil Registration" of Iran declared that more than 6 million of Iranians are Sayyid. The majority of Sayyids migrated to Iran from Arab lands predominantly in the 15th to 17th centuries during the Safavid era. The Safavids transformed the religious landscape of Iran by imposing Twelver Shiism on the populace.
If early catch-up growth does not occur and their heights remain below the third percentile by 2 or 3 years of age, adult height is likely to be similarly low. High-dose GH treatment has been shown to accelerate growth, but data on long term benefits and risks are limited. Idiopathic short stature (ISS) is one of the most controversial indications for GH as pediatric endocrinologists do not agree on its definition, diagnostic criteria, or limits. The term has been applied to children with severe unexplained shortness that will result in an adult height below the 3rd percentile. In the late 1990s, the pharmaceutical manufacturer Eli Lilly and Company sponsored trials of their brand of rHGH (Humatrope) in children with extreme ISS, those at least 2.25 standard deviations below mean (in the lowest 1.2 percent of the population). These boys and girls appeared to be headed toward heights of less than 63" (160 cm) and 59" (150 cm) respectively. They were treated for about 4 years and gained 1.5–3 in (3.8–7.6 cm) in adult height. Controversy has arisen as to whether all of these children were truly "short normal" children, since the average IGF1 was low. Approval of HGH for the treatment of this extreme degree of shortness led to an increase in the number of parents seeking its use to make otherwise normal children a little taller.